Basiliximab (DB00074) and Daclizumab (DB00111) are antibodies to IL2RB. Basiliximab is used as an immunosuppressive therapy in kidney transplant patients, whereas Daclizumab treats relapsed multiple sclerosis by blocking the interleukin-2 receptor. Here, IL2RB is linked to multiple sclerosis.